ADA 2027 is expected to feature extensive programming on GLP-1 receptor agonists and dual incretin therapies. Building on landmark data from recent years, sessions will present new outcomes data on next-generation GLP-1 drugs and combination therapies such as GLP-1 and GIP receptor agonists. Their cardioprotective and renal benefits, along with their expanding role in obesity management, are expected to be central themes.
Advanced diabetes technology will occupy a prominent place in the ADA 2027 program. Presentations on continuous glucose monitors, automated insulin delivery systems, and smart insulin pens will explore the latest clinical evidence and real-world implementation data. A major focus will be expanding the accessibility of these devices to a wider patient population including those with type 2 diabetes.
Cardiovascular and renal outcomes in diabetes will remain a core scientific focus at ADA 2027. Updated data on SGLT2 inhibitors, GLP-1 agonists, and combination strategies for cardiorenal protection are expected to feature in multiple plenary and symposium sessions. Precision medicine approaches using genomic and metabolomic data to individualize diabetes treatment will also be highlighted.
Additional program areas include type 1 diabetes immunotherapy, beta-cell preservation strategies, the role of gut microbiome in metabolic disease, diabetes and mental health, health disparities, pediatric diabetes, and gestational diabetes management. The Innovation Challenge will return, showcasing forward-thinking ideas from emerging researchers in the diabetes field.
June 2027
ADA 2027 Abstract Submission Guidelines
June 2027
